New RSV pill shows promise in early human trial
NCT ID NCT06170242
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental oral drug called EDP-323 in 142 healthy adults who were deliberately infected with RSV. The goal was to see if the drug is safe and can reduce the amount of virus in the nose compared to a placebo. Results will help determine if EDP-323 could be a future treatment for RSV.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
hVIVO Services Limited
London, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Nasal spray vaccine aims to shield infants from RSV
- Could a simple pill tame RSV? new trial tests obeldesivir
- New swab test aims to spot COVID, flu, and RSV in minutes
- New device aims to detect flu, RSV, and COVID-19 in one quick test
- RSV drug trial for kids under 5 halted early – only 4 children enrolled
- Triple-Threat vaccine aims to shield seniors from three respiratory viruses